ArticleClinical chemistry2002
Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity.
Article in Clinical chemistry, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00988364 (Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 in Patients With Metabolic Syndrome), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 in Patients With Metabolic Syndrome
Who cites it
19 citing papers in PubMed, 115 citations in OpenAlex.
- Lipid regulation in lipodystrophy versus the obesity-associated metabolic syndrome: the dissociation of HDL-C and triglycerides.The Journal of clinical endocrinology and metabolism · 2014Trial
- Visceral fat area and visceral-to-subcutaneous fat ratio are more strongly associated with residual cholesterol than conventional anthropometric indices in adults with type 2 diabetes.Frontiers in endocrinology · 2026Article
- Relationship of serum lipid parameters with kidney function decline accompanied by systemic arterial stiffness: a retrospective cohort study.Clinical kidney journal · 2023Article
- Anti-atherogenic and cardio-protective properties of sweet melon (Cucumis melo. L. Inodorus) seed extract on high fat diet induced obesity in male wistar rats.BMC complementary medicine and therapies · 2022Article
- Intestinal lipid absorption and transport in type 2 diabetes.Diabetologia · 2022Review
- Postprandial dyslipidemia in insulin resistant states in adolescent populations.Journal of biomedical research · 2020Article
- The Complex Interactions Between Obesity, Metabolism and the Brain.Frontiers in neuroscience · 2019Review
- Article
- Effect of Hypertriglyceridemia on Beta Cell Mass and Function in ApoC3 Transgenic Mice.The Journal of biological chemistry · 2016Article
- Article
- FoxO6 integrates insulin signaling with MTP for regulating VLDL production in the liver.Endocrinology · 2014Article
- Dyslipidemia in obesity: mechanisms and potential targets.Nutrients · 2013Review
- The chronic effects of fish oil with exercise on postprandial lipaemia and chylomicron homeostasis in insulin resistant viscerally obese men.Nutrition & metabolism · 2012Article
- Understanding postprandial inflammation and its relationship to lifestyle behaviour and metabolic diseases.International journal of vascular medicine · 2012Article
- Transplantation or removal of intra-abdominal adipose tissue prevents age-induced glucose insensitivity.Physiology & behavior · 2010Article
- FoxO1 integrates insulin signaling to VLDL production.Cell cycle (Georgetown, Tex.) · 2008Review
- PPAR{alpha} mediates the hypolipidemic action of fibrates by antagonizing FoxO1.American journal of physiology. Endocrinology and metabolism · 2007Article
- The vascular implications of post-prandial lipoprotein metabolism.The Clinical biochemist. Reviews · 2004Article
- Lipoprotein kinetics in the metabolic syndrome: pathophysiological and therapeutic lessons from stable isotope studies.The Clinical biochemist. Reviews · 2004Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundTriglyceride-rich lipoprotein remnants are atherogenic, and this may be particularly important in visceral obesity. We investigated remnant metabolism in obese men by measuring remnant-like particle-cholesterol (RLP-C), apolipoprotein (apo) B-48, apoC-III, and the clearance of a labeled remnant-like emulsion.
methodsFasting RLP-C, apoB-48, and apoC-III concentrations were measured in 48 viscerally obese men and 10 lean controls. RLP-C was determined by immunoseparation assay, apoB-48 by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and enhanced chemiluminescence, and apoC-III by immunoturbidimetric assay. The catabolism of chylomicron remnants was measured by intravenous injection of a remnant-like emulsion containing cholesteryl [(13)C]oleate, with isotopic enrichment of (13)CO(2) in breath determined by isotope-ratio mass spectrometry and a multicompartmental model to estimate fractional catabolic rate (FCR) of the emulsion.
resultsCompared with controls, obese men had significantly increased plasma concentrations of RLP-C, apoB-48, and apoC-III (P <0.001 for all). Plasma total apoB-100, non-HDL-cholesterol, LDL-cholesterol, triglycerides, and insulin resistance (HOMA score) were also significantly higher in the obese group (P <0.001 for all). Obese men had a significantly lower FCR of the remnant-like emulsion compared with controls (P = 0.020).
conclusionsViscerally obese individuals have insulin resistance and increased plasma concentrations of triglyceride-rich lipoprotein remnants, which may be attributable to decreased catabolism of these particles.
Indexed as
Identifiers
11805008W2130610669What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.